Acquisition by Michael Poirier of 14437 shares of Qualigen Therapeutics at 2.5405 subject to Rule 16b-3
QLGN Stock | USD 4.28 0.22 4.89% |
About 54% of Qualigen Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Qualigen Therapeutics suggests that some traders are interested. Qualigen Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Qualigen Therapeutics. Many technical investors use Qualigen Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Qualigen |
Filed transaction by Qualigen Therapeutics Director, Officer Chairman, President Ceo.. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Qualigen Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Qualigen Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Qualigen Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Qualigen Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Qualigen Therapeutics Fundamental Analysis
We analyze Qualigen Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Qualigen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Qualigen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Qualigen Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Qualigen Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Qualigen Therapeutics stock to make a market-neutral strategy. Peer analysis of Qualigen Therapeutics could also be used in its relative valuation, which is a method of valuing Qualigen Therapeutics by comparing valuation metrics with similar companies.
Peers
Qualigen Therapeutics Related Equities
IMMX | Immix Biopharma | 5.94 | ||||
ATNF | 180 Life | 3.83 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
ALRN | Aileron Therapeutics | 0.93 | ||||
ZVSA | ZyVersa Therapeutics | 1.75 | ||||
INDP | Indaptus Therapeutics | 2.00 | ||||
ENTX | Entera Bio | 2.18 | ||||
SLRX | Salarius Pharmaceuticals | 2.47 | ||||
KPRX | Kiora Pharmaceuticals | 3.57 | ||||
PHIO | Phio Pharmaceuticals | 3.91 | ||||
VRAX | Virax Biolabs | 6.08 | ||||
ASMB | Assembly Biosciences | 6.46 | ||||
REVB | Revelation Biosciences | 6.67 | ||||
NTRB | Nutriband | 15.29 |
Check out Qualigen Therapeutics Hype Analysis, Qualigen Therapeutics Correlation and Qualigen Therapeutics Performance. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.6 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.